natgillin/translations-raw huggingface dataset:
The incidence of pregnancy loss by miscarriage or abortion is higher in patients undergoing stimulation of follicular growth for ovulation induction than following natural conception. 
Pojavnost prekinitev nosečnosti zaradi spontanega splava ali abortusa je višja pri bolnicah, pri katerih stimulirajo rast foliklov za indukcijo ovulacije, kot po naravni zanositvi.
This may be associated with other risk factors such as OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovarian syndrome. 
To je lahko povezano z ostalimi dejavniki tveganja, kot so OHSS, nosečnost, predhodne operacije v trebušni votlini, zasuk jajčnika v anamnezi, predhodna ali trenutna cista jajčnika ali sindrom policističnega jajčnika.
In patients undergoing Assisted Reproductive Technology (ART) procedures the risk of multiple pregnancy is related mainly to the number of embryos replaced, their quality and the patient age. 
Pri bolnicah, ki so bile udeležene v postopkih oploditve z biomedicinsko pomočjo (ART), je tveganje za večplodno nosečnost povezano predvsem s številom prenesenih zarodkov, njihovo kakovostjo in starostjo bolnice.
At doses of 10 IU/kg/day and greater, repeated administration of lutropin alfa to pregnant rats and rabbits caused impairment of reproductive function including resorption of foetuses and reduced body weight gain of the dams. 
Pri odmerkih 10 i.e./kg/dan in več je ponovno dajanje lutropina alfa brejim podganam in zajkljam povzročilo okvare reproduktivne funkcije, vključno z resorpcijo fetusov in zmanjšanjem pridobivanja telesne mase samic.
Driving and using machines Luveris has no or negligible influence on the ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Luveris nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
This medicinal product must not be administered as a mixture in the same injection with other medicinal products except follitropin alfa. 
Zdravila ne smemo dajati kot mešanico v isti injekciji z drugimi zdravili, razen s folitropinom alfa.
• Remove the protective cap from the solvent vial. 
• Odstranite zaščitno kapico z viale z vehiklom.
Marketing Authorisation Holder Merck Europe B.V. 
Imetnik dovoljenja za promet z zdravilom Merck Europe B.V.
Luveris should be given as a course of daily injections simultaneously with FSH. 
Zdravilo Luveris moramo dajati kot serijo dnevnih injekcij sočasno s FSH-jem.
Lutropin alfa is produced in genetically engineered Chinese Hamster Ovary (CHO) cells. 
Lutropin alfa je pridobljen z gensko rekombinantno tehnologijo na ovarijskih celicah kitajskega hrčka (CHO).
When undergoing assisted reproductive technology the risk of having a multiple pregnancy is related to your age, the quality and the number of fertilised eggs or embryos placed inside you. 
Če poskušate zanositi z biomedicinsko pomočjo, je tveganje za večplodno nosečnost povezano z vašo starostjo, kakovostjo in številom oplojenih jajčec ter vsajenih zarodkov.
Name and address of the manufacturer of the biological active substance Merck Serono SA 
Ime in naslov izdelovalca biološke zdravilne učinkovine Merck Serono S.A.
Luveris is indicated for the stimulation of follicular development, in association with FSH (see section 4.1). 
Zdravilo Luveris je indicirano za uporabo pri stimulaciji nastajanja foliklov v povezavi s FHS (glejte poglavje 4.1).
Turn the vial upside down and gently draw the solution back into the syringe. 
Obrnite vialo navpično navzdol in previdno potegnite raztopino nazaj v brizgo.
In clinical trials, Luveris has been shown to increase the ovarian sensitivity to follitropin alfa. 
V kliničnih preskušanjih se je pokazalo, da zdravilo Luveris poveča občutljivost jajčnikov na folitropin alfa.
The prevalence of ectopic pregnancy after ART was reported to be higher than in the general population. 
Poročali so o višji prevalenci zunajmaternične nosečnosti po ART v primerjavi s splošno populacijo.
• Prepare the injection solution: Remove the protective cap from the Luveris powder vial, pick up your syringe and slowly inject the solvent into the vial of Luveris. 
• Pripravite raztopino za injiciranje: Odstranite zaščitno kapico z viale s praškom zdravila Luveris, vzemite brizgo in počasi injicirajte vehikel v vialo z zdravilom Luveris.
QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 75 IU of lutropin alfa (recombinant human Luteinising Hormone {r-hLH}). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena viala vsebuje 75 i.e. lutropina alfa (rekombinantnega humanega luteinizirajočega hormona, r-hLH).
• The usual starting dose is 75 IU (1 vial) of Luveris together with 75 IU or 150 IU of FSH. 
• Običajni začetni odmerek je 75 i.e. (1 viala) zdravila Luveris, skupaj s 75 i.e. ali 150 i.e.
In this case Luveris should be reconstituted first and then used to reconstitute the follitropin alfa powder. 
V takem primeru moramo najprej rekonstituirati zdravilo Luveris in ga nato uporabimo za rekonstitucijo praška folitropina alfa.
Birth defects after Assisted Reproductive Technology (ART) may be slightly higher than after spontaneous conceptions. 
Prirojene okvare po oploditvah z biomedicinsko pomočjo (Assisted Reproductive Technology - ART) so lahko nekoliko višje kot po spontani zanositvi.
• tumours of the hypothalamus and pituitary gland 
• s tumorji hipotalamusa in hipofize
Attach the reconstitution needle to the syringe and draw up some air into the syringe by pulling the plunger to approximately the 1 ml mark. Then, insert the needle into the vial, push the plunger to expel the air, turn the vial upside down and gently draw up all the solvent. 
Pritrdite iglo za rekonstituiranje na brizgo in potegnite vanjo nekaj zraka, tako da potisnete bat približno do oznake 1 ml. Nato vstavite iglo v vialo, potisnete bat, da iztisnete zrak, obrnite vialo navpično navzdol in nežno potegnite v brizgo ves vehikel.
Common: Mild or moderate OHSS (including associated symptomatology), ovarian cyst, breast pain, pelvic pain 
Pogosti: blagi do zmerni OHSS (vključno s povezano simptomatologijo), cista jajčnikov, bolečine v prsih, bolečine v medenici
INFORMATION IN BRAILLE luveris 75 iu 
PODATKI V BRAILLOVI PISAVI luveris 75 i.e.
Paediatric population There is no relevant indication for the use of Luveris in the paediatric population. 
Pediatrična populacija Zdravilo Luveris ni primerno za uporabo pri pediatrični populaciji.
• Lutropin alfa is recombinant human Luteinising Hormone (r-hLH), produced by recombinant DNA technology. 
• Lutropin alfa je rekombinantni humani luteinizirajoči hormon (r-hLH), proizveden z rekombinantno DNA tehnologijo.
• If you have ovarian enlargement or sacs of fluid within the ovaries (ovarian cyst) of unknown origin. 
• če imate povečanje jajčnika ali vrečke s tekočino v jajčnikih (cisto jajčnikov), ki je neznanega izvora,
Immediately withdraw the needle and clean the skin with an alcohol swab using a circular motion. 
Takoj izvlecite iglo in s krožnimi gibi z alkoholno blazinico očistite kožo.
• If you have cancer of ovaries, uterus or breast. 
• če so ugotovili, da imate raka jajčnikov, maternice ali dojke,
Do not use Luveris as a mixture with other medicines in the same injection, except for follitropin alfa, if prescribed by your doctor. 
Zdravila Luveris ne smemo dajati kot mešanico z drugimi zdravili v isti injekcijski brizgi, razen s folitropinom alfa, če vam ga je predpisal zdravnik.
In a clinical trial, mild and moderate injection site reactions (bruising, pain, redness, itching or swelling) were reported in 7.4 % and 0.9 % of the injections, respectively. 
V kliničnih preskušanjih so poročali o blagih in zmernih reakcijah na mestu injiciranja v 7,4 % oziroma 0,9 % (modrica, bolečina, rdečica, srbenje ali oteklina).
Therefore, if signs of ovarian hyperstimulation occur, it is recommended that hCG be withheld and the patient be advised to refrain from coitus or use barrier contraceptive methods for at least 4 days. 
Če se torej pojavijo znaki hiperstimulacije jajčnikov, je priporočljivo, da dajanje hCG prekinete, bolnicam pa svetujemo, da v obdobju najmanj 4 dni nimajo spolnih odnosov ali da v tem času uporabljajo mehanska kontracepcijska sredstva.
After ovulation, LH stimulates progesterone production in the corpus luteum by increasing the conversion of cholesterol to pregnenolone. 
Po ovulaciji LH v rumenem telescu spodbuja tvorbo progesterona, tako da poveča pretvorbo holesterola v pregnenolon.
Lutropin alfa is a recombinant human Luteinising Hormone (r-hLH), a glycoprotein composed of noncovalently bound α- and ß-subunits. 
Lutropin alfa je rekombinantni humani luteinizirajoči hormon (r-hLH), glikoprotein sestavljen iz dveh nekovalentno povezanih α- in β-podenot.
What Luveris looks like and contents of the pack 
Izgled zdravila Luveris in vsebina pakiranja
Ectopic pregnancy may also occur, especially in women with a history of prior tubal disease. 
Pojavi se lahko tudi zunajmaternična nosečnost, še posebej pri ženskah z boleznijo jajcevodov v anamnezi.
You and your partner's fertility should be evaluated before the treatment is started. 
Pred začetkom zdravljenja je treba oceniti vašo plodnost in plodnost vašega partnerja.
In case of exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of Luveris. 
Za zdravilo Luveris ni na voljo kliničnih podatkov od nosečnic, ki so bile izpostavljene zdravilu, da bi izključili teratogene učinke zdravila Luveris.
Inject the solution by pushing gently on the plunger. 
Raztopino vbrizgavajte tako, da nežno pritiskate na bat.
Luveris may be mixed with follitropin alfa and co-administered as a single injection. 
Zdravilo Luveris lahko mešamo s folitropinom alfa in dajemo sočasno kot eno samo injekcijo.
Gently flick the top section of the ampoule so that any fluid in the neck of the ampoule drops into the bottom chamber. 
Nežno krcnite po vrhnjem delu ampule, tako da vsa tekočina, ki je še morda v vratu ampule, odkaplja v spodnji predel.
These may be the symptoms of Ovarian Hyper-Stimulation Syndrome (OHSS). 
To so lahko simptomi sindroma hiperstimulacije jajčnikov (OHSS).
Up to 3 containers of powder may be dissolved in 1 ml of solvent. 
V 1 ml vehikla se lahko raztopi vsebina do 3 vial praška.
• Lower abdominal pain together with nausea or vomiting. 
• Bolečina v spodnjem delu trebuha skupaj s slabostjo ali bruhanjem.
Do not use this medicine after the expiry date, which is stated on the vials after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na vialah poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
• Luveris comes as a powder and solvent for solution for injection. 
• Zdravilo Luveris je na voljo kot prašek in vehikel za raztopino za injiciranje.
There have been reports of tumours in the ovaries and other sex organs, both benign and malignant, in women who have undergone multiple drug regimens for infertility treatment. 
Obstajajo poročila o tumorjih na jajčnikih in drugod na spolnih organih, ki so lahko benigni in maligni, pri ženskah, ki so bile izpostavljene režimom zdravljenja neplodnosti z več zdravili.
Breast-feeding Luveris is not indicated during breast-feeding. 
Dojenje Zdravilo Luveris ni indicirano med dojenjem.
In the ovaries, during the follicular phase, LH stimulates theca cells to secrete androgens, which will be used as the substrate by granulosa cell aromatase enzyme to produce estradiol, supporting FSH-induced follicular development. 
Med folikularno fazo LH v jajčnikih spodbuja celice teka, da izločajo androgene, ki so substrat encimu aromatazi celic granuloza za tvorbo estradiola, ki podpira s FSH-jem sprožen razvoj foliklov.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
• The other ingredients of the powder are polysorbate 20, sucrose, sodium dihydrogen phosphate monohydrate, disodium phosphate dihydrate, concentrated phosphoric acid, sodium hydroxide, L-methionine and nitrogen. 
• Druge sestavine praška so polisorbat 20, saharoza, natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat dihidrat, koncentrirana fosforjeva(V) kislina, natrijev hidroksid, L-metionin in dušik.
There is no indication for the use of Luveris during pregnancy. 
Ni zadostnih podatkov o uporabi zdravila Luveris pri nosečnicah.
Single doses of up to 40,000 IU of lutropin alfa have been administered to healthy female volunteers without serious adverse reactions and were well tolerated. 
Zdrave prostovoljke, ki so prejele enkratni odmerek do 40.000 i.e. lutropina alfa, so zdravilo prenašale dobro in brez resnih neželenih učinkov.
Find a clean area and lay out everything: one vial of Luveris, one vial of solvent, two alcohol swabs, one syringe, one reconstitution needle for dissolving the powder in the solvent, a fine-bore needle for subcutaneous injection, a sharps container for safe disposal of glass and needles. 
Poiščite čisto površino in vse razpostavite: eno vialo zdravila Luveris, eno vialo vehikla, dve alkoholni blazinici, eno brizgo, eno iglo za rekonstitucijo za raztapljanje praška v vehiklu, fino iglo za podkožno injiciranje, zaščitno posodo za varno odstranjevanje stekla in igel.
Now press the ampoule firmly over the neck, and break the ampoule away from the coloured dot. 
Zdaj trdno pritisnite na vrat ampule in jo odlomite stran od obarvane pike.
When an optimal response is obtained, a single injection of 250 microgramsof r-hCG or 5,000 IU to 10,000 IU hCG should be administered 24-48 hours after the last Luveris and FSH injections. 
Ko dosežemo optimalni odziv, moramo v 24-48 urah po zadnji injekciji zdravila Luveris in FSH-ja dati eno samo injekcijo z 250 mikrogrami r-hCG ali s 5.000 i.e. do 10.000 i.e. hCG-ja. Bolnici svetujemo, da ima spolni odnos na sam dan in dan po tistem, ko je dobila hCG.
How to use Luveris 
Kako uporabljati zdravilo Luveris
• Each vial of powder contains 75 IU of lutropin alfa and each vial of solvent contains 1 ml of water for injection. 
• Vsaka viala s praškom vsebuje 75 i.e. lutropina alfa in vsaka viala z vehiklom vsebuje 1 ml vode za injekcije.
• Each vial of powder contains 75 IU of lutropin alfa and each ampoule of solvent contains 1 ml of water for injection. 
• Vsaka viala s praškom vsebuje 75 i.e. lutropina alfa in ena ampula z vehiklom vsebuje 1 ml vode za injekcije.
A certain degree of ovarian enlargement is an expected effect of controlled ovarian stimulation. 
Pričakovan učinek nadzorovane stimulacije jajčnikov je določena stopnja povečanja jajčnikov.
More user-friendly presentations are available for self administration by patients at home. 
Na voljo so tudi druge, bolnicam bolj prijazne, oblike zdravila, ki jim omogočajo, da si lahko dajejo zdravilo same doma.
Women with a history of tubal disease are at risk of ectopic pregnancy (pregnancy where the embryo is implanted outside the womb), whether the pregnancy is obtained by spontaneous conception or with fertility treatments. 
Pri ženskah z boleznijo jajcevodov v anamnezi obstaja zvišano tveganje zunajmaternične nosečnosti (nosečnosti, kjer se zarodek ugnezdi zunaj maternice), bodisi ob spontanem spočetju ali po zdravljenju plodnosti.
Firmly pinch the skin together and insert the needle at a 45° to 90° angle using a dart-like motion. 
Trdno stisnite kožo in z gibom, podobnim metu sulice, zabodite iglo pod kotom 45º do 90º.
Luveris 75 IU Powder for injection Lutropin alfa Subcutaneous use 
Luveris 75 i.e. prašek za injekcijo lutropin alfa subkutana uporaba
The prevalence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. 
Prevalenca kongenitalnih malformacij po oploditvah z biomedicinsko pomočjo (Assisted Reproductive Technology - ART) je lahko rahlo višja kot po spontanem spočetju.
The medicine is used together with another hormone called Follicle Stimulating Hormone, (FSH), to bring about the development of follicles which are in the ovary, the structures maturing the eggs (ova). 
Zdravilo se uporablja v kombinaciji z drugim hormonom, ki se imenuje folikle stimulirajoči hormon, FSH, za spodbujanje razvoja foliklov, ki se nahajajo v jajčniku, v strukturi, v katerih zorijo jajčeca (ova).
The powder must be reconstituted with the solvent before use by gentle swirling. 
Pred uporabo moramo prašek rekonstituirati z vehiklom z blagim vrtinčenjem.
Other ingredients: polysorbate 20, sucrose, sodium dihydrogen phosphate monohydrate, disodium phosphate dihydrate, phosphoric acid concentrated, sodium hydroxide, L-methionine and nitrogen. 
Druge sestavine zdravila so: polisorbat 20, saharoza, natrijev dihidrogenfosfat monohidrat, natrijev hidrogenfosfat dihidrat, koncentrirana fosforjeva(V) kislina, natrijev hidroksid, L-metionin in dušik.
Luveris is used for the stimulation of follicular development in association with follitropin alfa. 
Zdravilo Luveris se uporablja za spodbujanje folikularnega razvoja skupaj s folitropinom alfa.
In LH and FSH deficient women, the objective of Luveris therapy in association with FSH is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotropin (hCG). 
Pri ženskah s pomanjkanjem LH-ja in FSH-ja je cilj terapije z zdravilom Luveris v kombinaciji s FSH-jem razvoj enega samega dozorelega Graafovega folikla, iz katerega se bo po dajanju humanega horionskega gonadotropina (hCG-ja) sprostil oocit.
At mid-cycle, high levels of LH trigger corpus luteum formation and ovulation. 
V sredini cikla visoka raven LH sproži tvorbo rumenega telesca in ovulacijo.
Mild manifestations of OHSS may include abdominal pain, abdominal discomfort and distension, or enlarged ovaries. 
Blago izražanje OHSS lahko vključuje bolečino v trebuhu, neprijeten občutek v trebuhu in napihnjenost ali povečanje jajčnikov.
Your doctor will ensure careful monitoring of ovarian response, based on ultrasound and blood sampling before and during the course of treatment. 
Pred samim zdravljenjem in tudi med njim bo zdravnik poskrbel za skrbno spremljanje ovarijskega odziva z ultrazvokom in jemanjem vzorcev krvi.
• Change the needle for the fine-bore needle and remove any air bubbles: If you see air bubbles in the syringe, hold the syringe with the needle pointing upwards and gently flick the syringe until all the air collects at the top. 
• Zamenjajte iglo s fino iglo za injiciranje in odstranite morebitne zračne mehurčke: če vidite mehurčke zraka v brizgi, jo držite tako, da igla gleda navzgor in nežno krcajte brizgo, da se ves zrak zbere na vrhu.
STATEMENT OF ACTIVE SUBSTANCE(S) Composition: one vial of powder contains: lutropin alfa 75 IU. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Sestava: ena viala s praškom vsebuje: lutropin alfa 75 i.e.
• It is supplied in packs containing 1, 3 or 10 vials of powder, together with the same number of solvent ampoules. 
• Na voljo je v pakiranjih po 1, 3 ali 10 vial s praškom in enakim številom ampul z vehiklom.
Severe OHSS further includes symptoms such as severe ovarian enlargement, weight gain, dyspnoea or oliguria. 
Huda stopnja OHSS pa vključuje simptome, kot so izredno povečanje jajčnikov, povečanje telesne mase, dispneja ali oligurija.
• According to your response, your doctor may increase your dose of FSH by preferably 
• Glede na vaš odziv lahko vaš zdravnik poveča odmerek FSH-ja po možnosti za 37,5 i.e.
Packs of 1, 3 or 10 vials with the corresponding number of solvent vials or ampoules. 
Pakiranja po 1, 3 ali 10 vial s praškom in enakim številom vial z vehiklom ali ampul z vehiklom.
Non clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti in kancerogenega potenciala ne kažejo posebnega tveganja za človeka.
Luveris in association with a Follicle Stimulating Hormone (FSH) preparation is recommended for the stimulation of follicular development in adult women with severe Luteinising Hormone (LH) and FSH deficiency. 
Zdravilo Luveris je skupaj s preparatom, ki vsebuje folikle stimulirajoči hormon (FSH), indicirano za spodbujanje folikularnega razvoja pri odraslih ženskah s hudim pomanjkanjem luteinizirajočega hormona (LH) in FSH.
Reproductive system neoplasms 
Novotvorbe na reprodukcijskem sistemu
There have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple treatment regimens for infertility. 
Obstajajo poročila o novotvorbah na jajčnikih in drugod na reprodukcijskem sistemu, ki so lahko benigne in maligne, pri ženskah, ki so bile izpostavljene več režimom zdravljenja neplodnosti.
• It is supplied in packs containing 1, 3 or 10 vials of powder, together with the same number of solvent vials. 
• Na voljo je v pakiranjih po 1, 3 ali 10 vial s praškom in enakim številom vial z vehiklom.
Moderate OHSS may additionally present with nausea, vomiting, ultrasound evidence of ascites or marked ovarian enlargement. 
Srednja stopnja OHSS lahko poleg tega vključuje tudi slabost, bruhanje, ultrazvočno dokazani ascites ali izrazito povečanje jajčnikov.
Ovarian Hyper-Stimulation Syndrome 
Sindrom hiperstimulacije jajčnikov
In the stimulation of follicular development in anovulatory women deficient in LH and FSH, the primary effect resulting from administration of lutropin alfa is an increase in estradiol secretion by the follicles, the growth of which is stimulated by FSH. 
Primarni učinek dajanja lutropina alfa za spodbujanje folikularnega razvoja pri ženskah brez ovulacije s pomanjkanjem LH in FSH, je povečano izločanje estradiola iz foliklov, katerih rast spodbuja FSH.
• Open the ampoule of solvent: On the head of the solvent ampoule, you will see a small coloured dot. 
• Odprite ampulo z vehiklom: Na kapici ampule z vehiklom boste opazili majhno obarvano piko.
The pharmacokinetics of lutropin alfa have been studied in pituitary desensitised female volunteers from 75 IU up to 40,000 IU. 
Farmakokinetične lastnosti lutropina alfa so proučevali na hipofizno desenzitiziranih prostovoljkah v odmerku od 75 i.e. do 40.000 i.e. Farmakokinetični profil lutropina alfa je podoben profilu hLH urinskega izvora.
Ectopic pregnancy (embryo implanted outside the womb) may occur especially in women with a history of prior tubal disease. 
Pojavi se lahko tudi zunajmaternična nosečnost (zarodek ugnezden izven maternice), še posebej pri ženskah, ki so imele bolezni jajcevodov.
When the desired response has been obtained, a single injection of hCG is given 24 to 48 hours after the last injections of Luveris and FSH. 
Ko je dosežen želeni odziv, se v 24 do 48 urah po zadnji injekciji zdravila Luveris in FSH-ja injicira ena sama injekcija hCG-ja. Priporočamo vam, da imate spolni odnos na isti dan in na dan, ki sledi dajanju hCG-ja.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Solvent for Luveris 
IME ZDRAVILA IN POT(I ) UPORABE vehikel za zdravilo Luveris voda za injekcije s.c.
Luveris should be administered concomitantly with follitropin alfa. 
Zdravilo Luveris se daje sočasno s folitropinom alfa.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING LUVERIS 75 IU, VIALS 
PODATKI NA ZUNANJI OVOJNINI LUVERIS 75 i.e., VIALE
• Sacs of fluid within the ovaries (ovarian cysts), breast pain and pelvic pain. 
• vrečke s tekočino v jajčnikih (ciste na jajčnikih), bolečine v prsnem košu in bolečine v medenici
In vitro the affinity binding of recombinant hLH to the LH/CG receptor on Leydig tumour cells (MA-10) is between that for hCG and that of pituitary hLH, but within the same order of magnitude. 
Ta LH/CG transmembranski receptor sodi v superdružino receptorjev z G proteini, za katere je značilen velik ekstracelularni del. In vitro je afiniteta vezave rekombinantnega hLH na LH/CG receptor na Leydigovih tumorskih celicah (MA-10) med afiniteto hCG-ja in hipofiznega hLH, vendar v istem redu velikosti.